340B Rule Clarifying Parameters For Discount Drug Program Is Planned By Year-End, HRSA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Both pharmaceutical manufacturers and 340B hospitals seek more specifics on issues such as which patients are eligible to receive deeply discounted drugs through the program, how to contract with outside pharmacies and obligations of manufacturers and eligible hospitals.
You may also be interested in...
Senior Senators Seek Details On Government Audits Of 340B Entities
Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.
340B Drug Audits: HRSA Reviewing 51 Entities In 2012
In its first year of auditing 340B facilities for compliance with drug discount rules, the HHS agency is investigating 45 randomly selected entities and six “targeted” entities that are the subject of specific allegations of non-compliance. About 250 hospitals have been decertified from 340B and may have to pay back discounts to drug makers.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.